Table 3 Time from administration of reversal agents to recovery of TOFR to 0.7, 0.8, 0.9, and 1.0
Neostigmine group (n = 34) | Sugammadex group (n = 36) | p-value | |
|---|---|---|---|
Primary endpoint | |||
Recovery of TOFR to 0.9 | |||
Number of patients | 34 (100%) | 36 (100%) | |
Median [IQR], s | 278 [180–532] | 88 [46–145] | < 0.001 |
Secondary endpoints | |||
Recovery of TOFR to 0.7 | |||
Number of patients | 30 (88.2%) | 29 (80.6%) | |
Median [IQR], s | 149 [102–304] | 55 [33–76] | < 0.001 |
Recovery of TOFR to 0.8 | |||
Number of patients | 30 (88.2%) | 27 (75.0%) | |
Median [IQR], s | 195 [119–380] | 80 [44–109] | < 0.001 |
Recovery of TOFR to 1.0 | |||
Number of patients | 18 (52.9%) | 31 (86.1%) | |
Median [IQR], s | 358 [220–514] | 121 [81–192] | < 0.001 |
Recovery of TOFR to 0.9 within 5 min from reversal administration | 20 (58.8%) | 34 (94.4%) | < 0.001 |
Recovery of TOFR to 0.9 within 10 min from reversal administration | 28 (76.5%) | 36 (100%) | 0.002 |
Recovery of TOFR to 1.0 within 10 min from reversal administration | 20 (64.5%) | 36 (100%) | < 0.001 |
Time to extubation | |||
Median [IQR], min | 17.3 [11–34] | 11.7 [8–15] | 0.011 |
Time to discharge to the ward | |||
Median [IQR], min | 91 [64109] | 94 [77–110] | 0.572 |